ATARA Biotherapeutics (ATRA) Misses Q1 EPS by 35c

ATARA Biotherapeutics (NASDAQ: ATRA) reported Q1 EPS of ($0.72), $0.35 worse than the analyst estimate of ($0.37). Revenue for the quarter came in at $1.23 million versus the consensus estimate of $32.01 million.

For earnings history and earnings-related data on ATARA Biotherapeutics (ATRA) click here.

You May Also Be Interested In

• onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
• Hyperscale Data acquires 48.5 acres to expand Michigan campus
• Benchmark Reiterates Buy Rating on Kura Sushi USA Inc. (KRUS) Ahead of Q3 Print